Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab Plus Chemotherapy in Neoadjuvant Esophageal SCC
NCT06006650Phase 2Recruiting
- Sponsor
- Tangdu Hospital
- Start
- Aug 2022
- Primary completion
- Dec 2031
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Tangdu Hospital. Started Aug 2022; status: recruiting.
02
Drugs
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT06006650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06006650.